Hyderabad: City-based pharma giant Dr Reddy’s Laboratories (DRL)'s US subsidiary Dr Reddy’s Laboratories Inc has voluntarily recalled Zenatane (isotretinoin) capsules (in multiple strengths of 10mg, 20 mg, 30 mg and 40 mg) from the US market, latest information on the USFDA (United States Food and Drug Administration) website has revealed. The drug is used in the treatment of acne.

 The firm has recalled 24,582 cartons of Zenatane capsules in multiple strengths packaged in 30-count cartons (3 x 10 blister cards) on February 15, 2017. The status of recall is ‘ongoing’. The firm has recalled 4,032 cartons of Zenatane capsules, 40 mg, (expires in March 2018), 4,014 cartons of Zenatane capsules, 30 mg, (expires in December 2017), 12,132 cartons of Zenatane capsules, 20 mg, (two lots expire in November 2017 and other two lots expire in March 2018) and 4,404 cartons of Zenatane capsules, 10 mg, (expires in July 2017). Citing the reason of recall, the company said, “Failed dissolution specifications - low dissolution results at S3 stage.” The recall falls under Class-III, which according to the USFDA is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences. The drug has been manufactured by Cipla Limited’s unit at Kurkumbh in Maharashtra for DRL. The company launched Zenatane capsules, a generic version of Accutane (Isotretinoin Capsules USP), in the US market in March 2013. Accutane was developed by Hoffman-La Roche
 
 
